Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 2/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093713 | 0.95 | CCR9 (0.41) | RAB9AMAOBCCR2APPNPC1 | |
| SCHEMBL1093468 | 0.95 | RAB9A (0.39) | RAB9AMAOBAPPPTGDR2NPC1 | |
| SCHEMBL1093087 | 0.94 | PPARG (0.43) | RAB9AMAOBPTGDR2PPARG | |
| SCHEMBL1093424 | 0.94 | PPARG (0.42) | RAB9ACCR2PPARG | |
| SCHEMBL1093470 | 0.94 | NPC1 (0.43) | RAB9AMAOBAPPPTGDR2NPC1 | |
| SCHEMBL1093742 | 0.94 | RAB9A (0.41) | RAB9AMAOBCCR2APPNPC1 | |
| SCHEMBL1093744 | 0.93 | RAB9A (0.38) | RAB9AMAOBAPPPTGDR2NPC1 | |
| SCHEMBL1092532 | 0.93 | CCR9 (0.40) | RAB9AMAOBAPPPTGDR2NPC1 | |
| SCHEMBL1094000 | 0.93 | RAB9A (0.38) | RAB9AMAOBAPPPTGDR2NPC1 | |
| SCHEMBL1094241 | 0.91 | ABCB1 (0.44) | RAB9AMAOBCCR2APPNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185558-B1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF SAME | SANOFI SA (FR) | 2014-06-18 | — | — | EP | disclosed |
| US-8420817-B2 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20120165531-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-06-28 | — | — | US | disclosed |
| US-8153796-B2 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-04-10 | — | — | US | disclosed |
| US-20100173929-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173929-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | ZDHHC7, CNR2, HDAC3 | RAB9A 2582/4885MAOB 59/4885CCR2 1154/4885 |
| US-20120165531-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | ZDHHC7, CNR2, HDAC3 | RAB9A 2582/4885MAOB 59/4885CCR2 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.